Partner Article
America beckons for Onyx following major appointment
DRUG research firm Onyx Scientific has set out plans to grow its US presence after appointing a new business development director with global pedigree.
The £4m-a-year Sunderland company currently conducts around 25% of its business in North America – the world’s largest pharmaceutical market.
It is now aiming to step up its operations stateside with the appointment of Craig Loftus as director of new business development to drive its ambitious plans.
Mr Loftus has 25 years of commercial experience working for several large outfits including GE, Merck, Millpore and Stedim.
He said: “I am excited about working for such a high quality company as Onyx Scientific and am looking forward to leveraging previous relationships.
Managing director Dr Tony Flinn said: “Our ambition is to really grow the business as aggressively as we can, especially in the important US market. We have around 25% of business in the US and we hope to do more.”
This was posted in Bdaily's Members' News section by Ruth Mitchell .
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular morning National email for free.
Talent is an asset, not an operational resource
Taking advantage of the opportunities ahead
Accountability isn’t the enemy of empathy
Act now to avoid a last-minute tax scramble
How inner-city living can transform a city by the sea
Artificial intelligence's value is the time it gives back
Why we must break the magnetic pull of London
AI scepticism is healthy - inaction isn't
What does NPPF mean for planning gain and pricing?
What new NPPF rules mean for landowners
The hidden cost squeezing Britain's economy
Teesside deserves more than cashback devolution